{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(5)"],"submitter":["Appleman VA"],"funding":["Takeda Development Center Americas, Inc. (TDCA), Lexington, MA"],"pubmed_abstract":["The tumor microenvironment in solid tumors contains myeloid cells that modulate local immune activity. Stimulator of IFN gene (STING) signaling activation in these myeloid cells enhances local type-I IFN production, inducing an innate immune response that mobilizes adaptive immunity and reprograms immunosuppressive myeloid populations to drive antitumor immunity. In this study, we generated TAK-500, an immune cell-directed antibody-drug conjugate, to deliver a STING agonist to CCR2+ human cells and drive enhanced antitumor activity relative to nontargeted STING agonists. Preclinically, TAK-500 triggered dose-dependent innate immune activation in vitro. In addition, a murine TAK-500 immune cell-directed antibody-drug conjugate surrogate enhanced innate and adaptive immune responses both in "],"journal":["Cancer immunology research"],"pagination":["661-679"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12046323"],"repository":["biostudies-literature"],"pubmed_title":["Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody-Drug Conjugate TAK-500."],"pmcid":["PMC12046323"],"pubmed_authors":["Christensen CL","Wang CI","Huang J","Porciuncula A","Dong L","Haridas S","Abu-Yousif AO","Lineberry N","Ganno ML","Wang J","Lee MY","Parent A","Lee HM","Iartchouk N","Matsuda A","Rosentrater E","Hatten T","Arendt C","Zhang DM","Appleman VA","Piatkov KI","Xu H","Gregory RC","Yoneyama T","Maldonado Lopez AE","Schalper KA","Merrigan SA","Harbison CE"],"additional_accession":[]},"is_claimable":false,"name":"Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody-Drug Conjugate TAK-500.","description":"The tumor microenvironment in solid tumors contains myeloid cells that modulate local immune activity. Stimulator of IFN gene (STING) signaling activation in these myeloid cells enhances local type-I IFN production, inducing an innate immune response that mobilizes adaptive immunity and reprograms immunosuppressive myeloid populations to drive antitumor immunity. In this study, we generated TAK-500, an immune cell-directed antibody-drug conjugate, to deliver a STING agonist to CCR2+ human cells and drive enhanced antitumor activity relative to nontargeted STING agonists. Preclinically, TAK-500 triggered dose-dependent innate immune activation in vitro. In addition, a murine TAK-500 immune cell-directed antibody-drug conjugate surrogate enhanced innate and adaptive immune responses both in ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 May","modification":"2025-07-08T03:10:33.775Z","creation":"2025-07-08T03:10:33.775Z"},"accession":"S-EPMC12046323","cross_references":{"pubmed":["39918395"],"doi":["10.1158/2326-6066.CIR-24-0103"]}}